Technical analysis of Context Therapeutics Inc. (CNTX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Price Performance
| 1 month | -23.67% |
| 3 months | -40.02% |
| Year-to-date | -74.22% |
| 1 year | -56.69% |
| 3 years | -59.96% |
52-Week Range
| 52-week High | $3.62 |
| 52-week Low | $0.34 |
| Avg Volume (90d) | 2.3M |
Technical Indicators
| SMA 50 | $0.51 |
| SMA 200 | $1.61 |
| Beta | 1.83 |
| 30-day Volatility (annualised) | 115.3% |
| Price vs SMA 50 | -25.4% |
| Price vs SMA 200 | -76.5% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.09 | |
| 2025-11 | $1.12 | +2.8% |
| 2025-12 | $1.47 | +31.2% |
| 2026-01 | $2.61 | +77.6% |
| 2026-02 | $2.25 | -13.8% |
| 2026-03 | $2.62 | +16.4% |
| 2026-04 | $2.36 | -9.9% |
| 2026-05 | $2.85 | +20.8% |
| 2026-06 | $0.55 | -80.6% |
| 2026-07 | $0.60 | +8.2% |
| 2026-08 | $0.39 | -35.0% |
| 2026-09 | $0.38 | -2.7% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | $0.06 | $3M |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
Price
| Price | $0.38 |
| Market Cap | $35M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.91 |
| EV / EBITDA | 0.23 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 5.81 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 6.94 |